A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein

Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation of a potent and broadly neut...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Aimin, Chen, Zhifeng, Cox, Kara S., Su, Hua-Poo, Callahan, Cheryl, Fridman, Arthur, Zhang, Lan, Patel, Sangita B., Cejas, Pedro J., Swoyer, Ryan, Touch, Sinoeun, Citron, Michael P., Govindarajan, Dhanasekaran, Luo, Bin, Eddins, Michael, Reid, John C., Soisson, Stephen M., Galli, Jennifer, Wang, Dai, Wen, Zhiyun, Heidecker, Gwendolyn J., Casimiro, Danilo R., DiStefano, Daniel J., Vora, Kalpit A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742648/
https://www.ncbi.nlm.nih.gov/pubmed/31515478
http://dx.doi.org/10.1038/s41467-019-12137-1
Descripción
Sumario:Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation of a potent and broadly neutralizing RSV monoclonal antibody derived from a human memory B-cell. This antibody, RB1, is equipotent on RSV A and B subtypes, potently neutralizes a diverse panel of clinical isolates in vitro and demonstrates in vivo protection. It binds to a highly conserved epitope in antigenic site IV of the RSV fusion glycoprotein. RB1 is the parental antibody to MK-1654 which is currently in clinical development for the prevention of RSV infection in infants.

Ejemplares similares